Drug Combination Details
| General Information of the Combination (ID: C96829) | |||||
|---|---|---|---|---|---|
| Name | Paclitaxel NP Info | + | Decitabine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Phase 1 | [1] | ||
|
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [2] | |||
|
Renal cell carcinoma
[ICD-11: 2C90]
|
Investigative | [3] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PCNA | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
| DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
| PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
DAC could significantly increase the susceptibility of PC cells to PTX, and confirmed the synergy of DAC and PTX. | |||||
| Experiment 2 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | TGFB1 | Molecule Info | ||
| In-vitro Model | ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | ||
| Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | |||
| Caki-2 | CVCL_0235 | Renal cell carcinoma | Homo sapiens | |||
| NC 65 | Renal cell carcinoma | Homo sapiens | ||||
| In-vivo Model | 1*107 ACHN or Caki-1 cells were injected into the backs of each mouse. | |||||
| Experimental
Result(s) |
Paclitaxel in combination with 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma through VHL-TGFBI signaling. | |||||
